Abstract: Provided herein are methods and compositions related to EVs useful as therapeutic agents.

Abstract: Disclosed herein are circular RNAs and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.

Abstract: Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

Abstract: Disclosed herein are circular RNA s and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.

Abstract: Disclosed herein are circular RNA s and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.

Abstract: Provided herein are methods and compositions related to EVs useful as therapeutic agents.

Abstract: The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.

Abstract: Disclosed herein are circular RNAs and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.

Abstract: A non-transitory computer-readable storage medium comprising instructions stored thereon. When executed by at least one processor, the instructions may be configured to cause a computing system to at least receive a message, the message including a header, an encrypted symmetric key, and an encrypted body, decrypt the encrypted symmetric key using a private key to generate a decrypted symmetric key, decrypt the encrypted body using the decrypted symmetric key to generate a decrypted body, and store the header, the decrypted symmetric key, and the decrypted body in long-term storage.

Abstract: Provided herein are methods and pharmaceutical compositions related to processed microbial extracellular vesicles (pmEVs) that can be useful as therapeutic agents.

Abstract: Provided herein are methods and pharmaceutical compositions related to secreted microbial extracellular vesicles (smEVs) that can be useful as therapeutic agents.

Abstract: Provided herein are methods and compositions related to immune modulating Lactococcus strains useful as therapeutic agents. In certain embodiments, provided herein are methods of treating an immune disorder in a subject comprising administering to the subject a bacterial composition comprising Lactococcus lactis cremoris Strain A (ATCC Deposit Number PTA-125368).

Abstract: A non-transitory computer-readable storage medium comprising instructions stored thereon. When executed by at least one processor, the instructions may be configured to cause a computing system to at least receive a message, the message including a header, an encrypted symmetric key, and an encrypted body, decrypt the encrypted symmetric key using a private key to generate a decrypted symmetric key, decrypt the encrypted body using the decrypted symmetric key to generate a decrypted body, and store the header, the decrypted symmetric key, and the decrypted body in long-term storage.

Abstract: Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

Abstract: Provided herein are methods and compositions related to membrane preparations (MPs) useful as therapeutic agents.

Abstract: Provided herein are methods and compositions related to immune modulating Lactococcus strains useful as therapeutic agents. In certain embodiments, provided herein are methods of treating an immune disorder in a subject comprising administering to the subject a bacterial composition comprising Lactococcus lactis cremoris Strain A (ATCC Deposit Number PTA-125368).

Abstract: Provided herein are methods and compositions related to Blautia Strain A useful as therapeutic agents.

Abstract: Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.

Abstract: Provided herein are methods and compositions related to Veillonella bacteria useful as therapeutic agents.

Abstract: Provided herein are methods and compositions related to Veillonella bacteria useful as therapeutic agents.